Boston Scientific Acquires Fixate™ Tissue Band Device

FiXate was Anulex, now Boston

In short

Boston Scientific Corporation has acquired the fiXate™ Tissue Band from Anulex technologies, Inc. We last featured fiXate on our site a year ago as it gained an extended FDA clearance. The device is a novel suturing device that is designed to enable quick and simple placement of a suture to help secure a spinal cord stimulator (SCS) lead or pain pump catheter.

Background

Designed to manage chronic pain, spinal cord stimulators deliver electrical pulses from an implantable pulse generator to leads with stimulating contacts in order to mask pain signals traveling to the brain. The fiXate Tissue Band is intended to be an accessory to the leads/catheter component of Spinal Cord Stimulator/Pain Pump systems functioning to secure the lead to the fascia or inter-spinous/supra-spinous ligament.

Bench test data show that, on average, the fiXate Tissue Band can place a suture in under one minute. The semi-automated design provides ease of use for physicians and offers a minimally invasive inline design.

Boston Scientific introduced the device earlier this month at the annual meeting of the American Academy of Pain Medicine in Fort Lauderdale.

Physician comments

“Anchoring a lead can be a time consuming part of the SCS procedure, and lead migration resulting in the need for revision is a known complication of SCS,” said Richard Bowman, M.D., of the Center of Pain Relief in Charleston, West Virginia. “The fiXate device improves the surgical technique by allowing the lead anchor to be secured tightly to tissue in a quick and efficient way with a small anchoring incision.”

Company comments

“We are pleased to add the fiXate device to our expanding Neuromodulation portfolio,” said Maulik Nanavaty, president, Neuromodulation, Boston Scientific. “We believe the fiXate device is a significant advance for lead securement, and this acquisition demonstrates our commitment to bringing to the market innovations that are designed to improve patient outcomes.”

Source: Boston Scientific Corporation